Symbols / ARTL
ARTL Chart
About
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. The company's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated/ weight loss with cancer; and ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, depression, post-traumatic stress disorder PTSD, epilepsy and insomnia, pain and inflammation, and other potential indications. It also offers ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders. The company was formerly known as Reactive Medical Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 3.00M |
| Enterprise Value | 1.86M | Income | -12.49M | Sales | — |
| Book/sh | -0.41 | Cash/sh | 0.85 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | -1.48 | PEG | — |
| P/S | — | P/B | -3.19 | P/C | — |
| EV/EBITDA | — | EV/Sales | — | Quick Ratio | 0.35 |
| Current Ratio | 0.38 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -19.50 | EPS next Y | -0.88 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -136.26% |
| ROE | -4.36% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.31M |
| Shs Float | 2.01M | Short Float | 5.94% | Short Ratio | 1.27 |
| Short Interest | — | 52W High | 28.60 | 52W Low | 1.10 |
| Beta | 1.00 | Avg Volume | 491.23K | Volume | 48.97K |
| Target Price | — | Recom | None | Prev Close | $1.24 |
| Price | $1.30 | Change | 4.84% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$1.30
Latest analyst target
3. DCF / Fair value
$-27.00
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.30
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-19 | down | Maxim Group | Buy → Hold | — |
| 2025-09-08 | down | D. Boral Capital | Buy → Hold | — |
| 2025-08-26 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-07-08 | up | D. Boral Capital | Hold → Buy | $20 |
| 2025-06-11 | down | D. Boral Capital | Buy → Hold | — |
| 2025-06-06 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-04-28 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-04-02 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-03-03 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-02-27 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-01-14 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-12-09 | main | D. Boral Capital | Buy → Buy | $6 |
| 2024-12-09 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-06-05 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
| 2024-05-15 | reit | HC Wainwright & Co. | Buy → Buy | $5 |
- Cancer appetite, pain and depression drugs: Artelo’s 2025 trial gains - Stock Titan ue, 24 Feb 2026 13
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 24 Feb 2026 12
- Artelo Biosciences, Inc. Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative Mon, 29 Sep 2025 07
- Why Is Artelo Biosciences Stock (ARTL) Up 135% Today? - TipRanks Mon, 30 Jun 2025 07
- Artelo Biosciences Prices $3 Mln Public Offering Of Common Stock And Warrants - Nasdaq hu, 04 Sep 2025 07
- Why Keysight Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket - Benzinga ue, 24 Feb 2026 10
- $3 Million Capital Raise: Clinical-Stage Biotech Artelo Prices Public Offering for Cancer & Pain Research - Stock Titan hu, 04 Sep 2025 07
- Artelo Biosciences Announces Reverse Stock Split - Yahoo Finance Wed, 11 Jun 2025 07
- Why analysts upgrade ARTL stock - Portfolio Growth Summary & Fast Entry and Exit Trade Plans - mfd.ru Mon, 16 Feb 2026 11
- Artelo Biosciences Initiates SOL Treasury Strategy with PIPE Financing, Partnering with CUBE and Bartosz Lipiński - Quiver Quantitative Mon, 04 Aug 2025 07
- Aug PostEarnings: Will Intuit Inc stock hit new highs in YEAR - 2025 Market Trends & Community Consensus Trade Signals - baoquankhu1.vn Wed, 18 Feb 2026 20
- Artelo (Nasdaq: ARTL) study: FABP5 inhibitor reduces anxiety, depression in rats - Stock Titan Wed, 03 Dec 2025 08
- Artelo Biosciences’ ART12.11 Shows Promising Antidepressant Effects in Preclinical Study - Yahoo Finance Wed, 09 Jul 2025 07
- Artelo Biosciences faces new Nasdaq compliance challenges - TipRanks Fri, 16 Jan 2026 08
- 12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga hu, 19 Feb 2026 17
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 38346 | 136128 | — | Conversion of Exercise of derivative security at price 3.55 per share. | MATSUI CONNIE L | Director | — | 2025-10-28 00:00:00 | D |
| 1 | 9586 | 34030 | — | Conversion of Exercise of derivative security at price 3.55 per share. | GORGAS GREGORY D | Chief Executive Officer | — | 2025-10-28 00:00:00 | D |
| 2 | 6846 | 24303 | — | Conversion of Exercise of derivative security at price 3.55 per share. | FAVORITO TAMARA A. | Director | — | 2025-10-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-08-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -10.39M | -10.57M | -10.29M | -7.44M |
| TotalUnusualItems | 282.00K | 641.00K | 207.00K | 2.00K |
| TotalUnusualItemsExcludingGoodwill | 282.00K | 641.00K | 207.00K | 2.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -9.83M | -9.29M | -10.08M | -7.44M |
| EBITDA | -10.11M | -9.93M | -10.08M | -7.44M |
| EBIT | -10.11M | -9.93M | -10.08M | -7.44M |
| NetInterestIncome | 0.00 | -3.00K | 2.00K | |
| InterestExpense | 0.00 | 5.00K | 0.00 | |
| InterestIncome | 0.00 | 2.00K | 2.00K | |
| NormalizedIncome | -10.11M | -9.93M | -10.29M | -7.44M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -9.83M | -9.29M | -10.08M | -7.44M |
| TotalExpenses | 10.11M | 9.93M | 10.29M | 7.44M |
| TotalOperatingIncomeAsReported | -10.11M | -9.93M | -10.29M | -7.44M |
| DilutedAverageShares | 537.17K | 493.33K | 472.17K | 207.50K |
| BasicAverageShares | 537.17K | 493.33K | 472.17K | 207.50K |
| DilutedEPS | -18.30 | -18.84 | -21.36 | -35.82 |
| BasicEPS | -18.30 | -18.84 | -21.36 | -35.82 |
| DilutedNIAvailtoComStockholders | -9.83M | -9.29M | -10.08M | -7.44M |
| NetIncomeCommonStockholders | -9.83M | -9.29M | -10.08M | -7.44M |
| NetIncome | -9.83M | -9.29M | -10.08M | -7.44M |
| NetIncomeIncludingNoncontrollingInterests | -9.83M | -9.29M | -10.08M | -7.44M |
| NetIncomeContinuousOperations | -9.83M | -9.29M | -10.08M | -7.44M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -9.83M | -9.29M | -10.08M | -7.44M |
| OtherIncomeExpense | 282.00K | 641.00K | 207.00K | 2.00K |
| GainOnSaleOfSecurity | 282.00K | 641.00K | 207.00K | 2.00K |
| NetNonOperatingInterestIncomeExpense | 0.00 | -3.00K | 2.00K | |
| InterestExpenseNonOperating | 0.00 | 5.00K | 0.00 | |
| InterestIncomeNonOperating | 0.00 | 2.00K | 2.00K | |
| OperatingIncome | -10.11M | -9.93M | -10.29M | -7.44M |
| OperatingExpense | 10.11M | 9.93M | 10.29M | 7.44M |
| ResearchAndDevelopment | 5.99M | 5.70M | 4.32M | 2.84M |
| SellingGeneralAndAdministration | 4.12M | 4.23M | 5.96M | 4.60M |
| GeneralAndAdministrativeExpense | 4.12M | 4.23M | 5.96M | 4.60M |
| OtherGandA | 4.12M | 4.23M | 5.96M | 4.60M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 567.58K | 531.49K | 475.95K | 272.52K |
| ShareIssued | 567.58K | 531.49K | 475.95K | 272.52K |
| TotalDebt | 104.00K | 23.00K | 63.00K | 95.00K |
| TangibleBookValue | 818.00K | 9.71M | 17.36M | 10.00M |
| InvestedCapital | 2.86M | 11.75M | 19.40M | 12.04M |
| WorkingCapital | 785.00K | 9.69M | 17.32M | 9.79M |
| NetTangibleAssets | 818.00K | 9.71M | 17.36M | 10.00M |
| CapitalLeaseObligations | 104.00K | 23.00K | 63.00K | 95.00K |
| CommonStockEquity | 2.86M | 11.75M | 19.40M | 12.04M |
| TotalCapitalization | 2.86M | 11.75M | 19.40M | 12.04M |
| TotalEquityGrossMinorityInterest | 2.86M | 11.75M | 19.40M | 12.04M |
| StockholdersEquity | 2.86M | 11.75M | 19.40M | 12.04M |
| GainsLossesNotAffectingRetainedEarnings | -202.00K | -203.00K | -254.00K | 18.00K |
| OtherEquityAdjustments | -202.00K | -203.00K | -254.00K | 18.00K |
| RetainedEarnings | -50.14M | -40.31M | -31.02M | -16.90M |
| AdditionalPaidInCapital | 53.19M | 52.26M | 50.67M | 28.93M |
| CapitalStock | 3.00K | 3.00K | 3.00K | 2.00K |
| CommonStock | 3.00K | 3.00K | 3.00K | 2.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.84M | 1.29M | 1.02M | 593.00K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 69.00K | 0.00 | 23.00K | 67.00K |
| LongTermDebtAndCapitalLeaseObligation | 69.00K | 0.00 | 23.00K | 67.00K |
| LongTermCapitalLeaseObligation | 69.00K | 0.00 | 23.00K | 67.00K |
| CurrentLiabilities | 1.77M | 1.29M | 998.00K | 526.00K |
| OtherCurrentLiabilities | -3.00K | |||
| CurrentDebtAndCapitalLeaseObligation | 35.00K | 23.00K | 40.00K | 28.00K |
| CurrentCapitalLeaseObligation | 35.00K | 23.00K | 40.00K | 28.00K |
| PayablesAndAccruedExpenses | 1.74M | 1.27M | 958.00K | 498.00K |
| Payables | 1.74M | 1.27M | 958.00K | 498.00K |
| DuetoRelatedPartiesCurrent | 61.00K | 30.00K | 53.00K | 27.00K |
| AccountsPayable | 1.68M | 1.24M | 905.00K | 471.00K |
| TotalAssets | 4.70M | 13.04M | 20.42M | 12.63M |
| TotalNonCurrentAssets | 2.14M | 2.06M | 2.10M | 2.32M |
| OtherNonCurrentAssets | 3.00K | 3.00K | 3.00K | 189.00K |
| NonCurrentPrepaidAssets | 189.00K | |||
| InvestmentsAndAdvances | 0.00 | 0.00 | ||
| InvestmentinFinancialAssets | 0.00 | 0.00 | ||
| GoodwillAndOtherIntangibleAssets | 2.04M | 2.04M | 2.04M | 2.04M |
| OtherIntangibleAssets | 2.04M | 2.04M | 2.04M | 2.04M |
| NetPPE | 99.00K | 21.00K | 60.00K | 90.00K |
| GrossPPE | 99.00K | 21.00K | 60.00K | 90.00K |
| OtherProperties | 99.00K | 21.00K | 60.00K | 90.00K |
| BuildingsAndImprovements | 21.00K | 60.00K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 2.56M | 10.98M | 18.32M | 10.32M |
| OtherCurrentAssets | 219.00K | 554.00K | 789.00K | 252.00K |
| PrepaidAssets | 252.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 2.34M | 10.43M | 17.53M | 10.06M |
| OtherShortTermInvestments | 0.00 | 7.61M | 10.64M | 3.44M |
| CashAndCashEquivalents | 2.34M | 2.81M | 6.89M | 6.63M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-08-31 |
|---|---|---|---|---|
| FreeCashFlow | -8.35M | -8.21M | -8.01M | -6.14M |
| IssuanceOfCapitalStock | 112.00K | 567.00K | 0.00 | 8.10M |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 2.34M | 2.81M | 6.89M | 6.63M |
| BeginningCashPosition | 2.81M | 6.89M | 12.16M | 2.14M |
| EffectOfExchangeRateChanges | -8.00K | 60.00K | -224.00K | -45.00K |
| ChangesInCash | -469.00K | -4.13M | -5.05M | 4.53M |
| FinancingCashFlow | 112.00K | 567.00K | 0.00 | 14.11M |
| CashFlowFromContinuingFinancingActivities | 112.00K | 567.00K | 0.00 | 14.11M |
| NetOtherFinancingCharges | -7.00K | |||
| ProceedsFromStockOptionExercised | 0.00 | 6.02M | ||
| NetCommonStockIssuance | 112.00K | 567.00K | 0.00 | 8.10M |
| CommonStockIssuance | 112.00K | 567.00K | 0.00 | 8.10M |
| InvestingCashFlow | 7.77M | 3.51M | 2.96M | -3.44M |
| CashFlowFromContinuingInvestingActivities | 7.77M | 3.51M | 2.96M | -3.44M |
| NetInvestmentPurchaseAndSale | 7.77M | 3.51M | 2.96M | -3.44M |
| SaleOfInvestment | 8.25M | 17.19M | 16.18M | 2.66M |
| PurchaseOfInvestment | -481.00K | -13.69M | -13.22M | -6.10M |
| OperatingCashFlow | -8.35M | -8.21M | -8.01M | -6.14M |
| CashFlowFromContinuingOperatingActivities | -8.35M | -8.21M | -8.01M | -6.14M |
| ChangeInWorkingCapital | 937.00K | 703.00K | -172.00K | -242.00K |
| ChangeInPayablesAndAccruedExpense | 480.00K | 273.00K | 23.00K | -3.00K |
| ChangeInPayable | 480.00K | 273.00K | 23.00K | -3.00K |
| ChangeInAccountPayable | 480.00K | 273.00K | 23.00K | -3.00K |
| ChangeInPrepaidAssets | 457.00K | 430.00K | -195.00K | -239.00K |
| OtherNonCashItems | 3.00K | -4.00K | 5.00K | |
| StockBasedCompensation | 818.00K | 1.02M | 2.46M | 1.53M |
| UnrealizedGainLossOnInvestmentSecurities | -282.00K | -641.00K | -207.00K | 2.00K |
| NetIncomeFromContinuingOperations | -9.83M | -9.29M | -10.08M | -7.44M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARTL
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|